Cargando…

Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design

BACKGROUND: Vagal nerve stimulation (VNS) can be indicated in patients with drug-resistant epilepsy, who are not eligible for resective epilepsy surgery. In VNS therapy, the responder rate (i.e., percentage of subjects experiencing ≥50% seizure reduction) is ~50%. At the moment, there is no widely-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolezalova, Irena, Koritakova, Eva, Souckova, Lenka, Chrastina, Jan, Chladek, Jan, Stepanova, Radka, Brazdil, Milan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979018/
https://www.ncbi.nlm.nih.gov/pubmed/35386419
http://dx.doi.org/10.3389/fneur.2022.839163
_version_ 1784681082474463232
author Dolezalova, Irena
Koritakova, Eva
Souckova, Lenka
Chrastina, Jan
Chladek, Jan
Stepanova, Radka
Brazdil, Milan
author_facet Dolezalova, Irena
Koritakova, Eva
Souckova, Lenka
Chrastina, Jan
Chladek, Jan
Stepanova, Radka
Brazdil, Milan
author_sort Dolezalova, Irena
collection PubMed
description BACKGROUND: Vagal nerve stimulation (VNS) can be indicated in patients with drug-resistant epilepsy, who are not eligible for resective epilepsy surgery. In VNS therapy, the responder rate (i.e., percentage of subjects experiencing ≥50% seizure reduction) is ~50%. At the moment, there is no widely-accepted possibility to predict VNS efficacy in a particular patient based on pre-implantation data, which can lead to unnecessary surgery and improper allocation of financial resources. The principal aim of PRediction of vagal nerve stimulation EfficaCy In drug-reSistant Epilepsy (PRECISE) study is to verify the predictability of VNS efficacy by analysis of pre-implantation routine electroencephalogram (EEG). METHODS: PRECISE is designed as a prospective multicentric study in which patients indicated to VNS therapy will be recruited. Patients will be classified as predicted responders vs. predicted non-responders using pre-implantation EEG analyses. After the first and second year of the study, the real-life outcome (responder vs. non-responder) will be determined. The real-life outcome and predicted outcome will be compared in terms of accuracy, specificity, and sensitivity. In the meantime, the patients will be managed according to the best clinical practice to obtain the best therapeutic response. The primary endpoint will be the accuracy of the statistical model for prediction of response to VNS therapy in terms of responders and non-responders. The secondary endpoint will be the quantification of differences in EEG power spectra (Relative Mean Power, %) between real-life responders and real-life non-responders to VNS therapy in drug-resistant epilepsy and the sensitivity and specificity of the model. DISCUSSION: PRECISE relies on the results of our previous work, through which we developed a statistical classifier for VNS response (responders vs. non-responders) based on differences in EEG power spectra dynamics (Pre-X-Stim). TRIAL REGISTRATION: www.ClinicalTrials.gov, identifier: NCT04935567.
format Online
Article
Text
id pubmed-8979018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89790182022-04-05 Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design Dolezalova, Irena Koritakova, Eva Souckova, Lenka Chrastina, Jan Chladek, Jan Stepanova, Radka Brazdil, Milan Front Neurol Neurology BACKGROUND: Vagal nerve stimulation (VNS) can be indicated in patients with drug-resistant epilepsy, who are not eligible for resective epilepsy surgery. In VNS therapy, the responder rate (i.e., percentage of subjects experiencing ≥50% seizure reduction) is ~50%. At the moment, there is no widely-accepted possibility to predict VNS efficacy in a particular patient based on pre-implantation data, which can lead to unnecessary surgery and improper allocation of financial resources. The principal aim of PRediction of vagal nerve stimulation EfficaCy In drug-reSistant Epilepsy (PRECISE) study is to verify the predictability of VNS efficacy by analysis of pre-implantation routine electroencephalogram (EEG). METHODS: PRECISE is designed as a prospective multicentric study in which patients indicated to VNS therapy will be recruited. Patients will be classified as predicted responders vs. predicted non-responders using pre-implantation EEG analyses. After the first and second year of the study, the real-life outcome (responder vs. non-responder) will be determined. The real-life outcome and predicted outcome will be compared in terms of accuracy, specificity, and sensitivity. In the meantime, the patients will be managed according to the best clinical practice to obtain the best therapeutic response. The primary endpoint will be the accuracy of the statistical model for prediction of response to VNS therapy in terms of responders and non-responders. The secondary endpoint will be the quantification of differences in EEG power spectra (Relative Mean Power, %) between real-life responders and real-life non-responders to VNS therapy in drug-resistant epilepsy and the sensitivity and specificity of the model. DISCUSSION: PRECISE relies on the results of our previous work, through which we developed a statistical classifier for VNS response (responders vs. non-responders) based on differences in EEG power spectra dynamics (Pre-X-Stim). TRIAL REGISTRATION: www.ClinicalTrials.gov, identifier: NCT04935567. Frontiers Media S.A. 2022-03-21 /pmc/articles/PMC8979018/ /pubmed/35386419 http://dx.doi.org/10.3389/fneur.2022.839163 Text en Copyright © 2022 Dolezalova, Koritakova, Souckova, Chrastina, Chladek, Stepanova and Brazdil. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Dolezalova, Irena
Koritakova, Eva
Souckova, Lenka
Chrastina, Jan
Chladek, Jan
Stepanova, Radka
Brazdil, Milan
Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design
title Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design
title_full Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design
title_fullStr Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design
title_full_unstemmed Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design
title_short Prediction of Vagal Nerve Stimulation Efficacy in Drug-Resistant Epilepsy (PRECISE): Prospective Study for Pre-implantation Prediction/Study Design
title_sort prediction of vagal nerve stimulation efficacy in drug-resistant epilepsy (precise): prospective study for pre-implantation prediction/study design
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979018/
https://www.ncbi.nlm.nih.gov/pubmed/35386419
http://dx.doi.org/10.3389/fneur.2022.839163
work_keys_str_mv AT dolezalovairena predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign
AT koritakovaeva predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign
AT souckovalenka predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign
AT chrastinajan predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign
AT chladekjan predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign
AT stepanovaradka predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign
AT brazdilmilan predictionofvagalnervestimulationefficacyindrugresistantepilepsypreciseprospectivestudyforpreimplantationpredictionstudydesign